Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
South San Francisco-based Walking Fish started the week off strong by announcing its closing of a $50 million Series A financing round on Monday.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
Bolt Biotherapeutics was anything but quiet this summer.
Frederick Frank, an innovator of biotech investment who played a key role in Roche’s acquisition of Genentech and the merger that formed Bristol-Myers Squibb, has died.
SENS Research Foundation released findings that confirmed the charges of inappropriate behavior raised by two former female employees against Aubrey de Grey.
The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
Philip Dormitzer explained that there are plenty of reasons to be excited about the prophylactic and therapeutic potential of mRNA.